FDA Approvals, News & Updates

On August 16, 2018, the FDA accelerated the approval of nivolu­mab (Opdivo; Bristol-Myers Squibb) for the treatment of patients with metastatic small-cell lung cancer that progressed after platinum-based chemotherapy and ≥1 other lines of therapy. Read Article ›

On July 13, 2018, the FDA approved a new indication for enzalutamide (Xtandi; Astellas) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Enzalutamide was initially approved for metastatic CRPC in 2012. Read Article ›

Page 10 of 15

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: